# SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies

- Link: https://www.thailand-business-news.com/pr-news/synusight-shanghai-jiao-tong-university-collaboration-published-in-cell-advancing-diagnostic-classification-of-synucleinopathies
- Published: 2026-05-27T19:08:00+07:00
- Author: PR Newswire

SHANGHAI, May 27, 2026 /PRNewswire/ — SynuSight Biotech (SynuSight), a clinical-
stage biotech company focused on innovative pipeline development for neurodegenerative
diseases, today announced the publication of a collaborative study in _Cell_ with
Professor Dan Li’s team at the Bio-X Institute of Shanghai Jiao Tong University.

The study, titled ["TPPP/p25 amyloid seeding activity as a specific biomarker for multiple system atrophy"](https://www.cell.com/cell/fulltext/S0092-8674(26)00517-9)
was jointly conducted by Professor Dan Li’s team at the Bio-X Institute of Shanghai
Jiao Tong University; Professor Cong Liu’s team at the Interdisciplinary Research
Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese
Academy of Sciences; and Professor Jian Wang’s team at Huashan Hospital, Fudan University.

The research addresses the long-standing clinical challenges in the diagnosis and
classification of synucleinopathies such as multiple system atrophy. It developed
a new detection method based on the pathological amyloid seeding activity of TPPP/
p25, providing a novel research foundation and technological pathway for the molecular
classification and diagnosis of synucleinopathies.

Synucleinopathies are a group of neurodegenerative disorders characterized by the
abnormal aggregation of α-synuclein (α-syn). Representative diseases include Parkinson’s
disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB).
In early clinical stages, these diseases often present overlapping symptoms, including
bradykinesia, tremor, gait instability, balance impairment, and autonomic dysfunction.
As a result, symptom-based clinical diagnosis remains challenging, underscoring 
the need for diagnostic tools based on disease-specific pathological biomarkers.

Although both PD and MSA are associated with abnormal aggregation of α-synuclein,
they differ significantly in cellular pathology. PD is primarily characterized by
α-syn aggregation within neurons, leading to the formation of Lewy bodies and Lewy
neurites. In contrast, MSA is defined by α-syn accumulation within oligodendrocytes,
forming glial cytoplasmic inclusions (GCIs). Building on this pathological distinction,
the research team focused on TPPP/p25, a microtubule polymerization-promoting protein
selectively expressed in oligodendrocytes.

Mechanistic and structural studies showed that full-length TPPP/p25 normally maintains
a self-protective conformation that limits amyloid fibril formation. The CORE domain
was identified as the key region driving pathological TPPP/p25 aggregation, and 
disruption of this self-protective conformation may promote abnormal aggregation
under pathological conditions. Based on these findings, the research team designed
and screened miniCORE as an efficient amplification substrate and established the
TPPP/p25 seed amplification assay (TPPP/p25-SAA).

Clinical sample validation demonstrated that TPPP/p25-SAA can specifically detect
pathological TPPP/p25 seeds in cerebrospinal fluid (CSF) samples from patients with
MSA, with no detectable cross-reactivity to amyloid seeds associated with Aβ, tau,
or α-syn. The assay was able to effectively distinguish MSA from PD, DLB, and healthy
controls, supporting its potential as an MSA-specific CSF biomarker and a molecular
classification tool for synucleinopathies.

SynuSight Biotech is a clinical-stage biotechnology company dedicated to innovative
pipeline development for neurodegenerative diseases, with a long-term focus on the
development and clinical translation of diagnostic tools for such conditions. The
company has established an industry–academia–research collaboration with Professor
Dan Li’s team at Shanghai Jiao Tong University. Going forward, SynuSight will leverage
its expertise in α-synuclein PET tracer development, clinical research advancement,
and translational product development to continuously drive the translation of these
innovative achievements toward product development and clinical application.

About SynuSight Biotech:

SynuSight Biotech is committed to pioneering transformative diagnostic solutions
for neurodegenerative diseases through cutting-edge scientific expertise and innovative
technology platforms, ultimately benefiting millions of patients worldwide.  SynuSight
specializes in studying the misfolding and pathological aggregation of proteins 
such as alpha-synuclein, tau, and A-beta. By integrating cutting-edge technologies
like Cryo-EM electron diffraction, helical filament imaging, and In-cell NMR spectroscopy,
we have built unparalleled expertise in key neurodegenerative disease targets, unlocking
new possibilities for innovative therapeutic solutions development.

**Media Contact:[info@synusight.com](https://www.thailand-business-news.com/pr-news/info@synusight.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies ](http://www.prnasia.com/story/archive/4968795_CN68795_0?rand=184833)